Cabot
CBT · Diversified Chemicals
$73.79
0.7%Olin
OLN · Diversified Chemicals
$15.66
0.8%The short version
- Olin is the larger business, with $6.8B of revenue in fiscal 2025 against $3.7B for Cabot, about 1.8 times as much.
- Olin grew revenue faster (3.7%, against −7.0%).
- Cabot kept more of each dollar of sales as operating profit (16.7% operating margin, against 0.1% operating margin).
- Cabot turned more of its sales into free cash flow (10.5% FCF margin, against 3.7% FCF margin).
- Cabot earned a higher return on the capital invested in it (15.9%, against 0.1%).
| Latest fiscal year | CBT · FY25 | OLN · FY25 |
|---|---|---|
| Size | ||
| Market cap | $3.9B | $1.8B |
| Revenue | $3.7B | $6.8B |
| Free cash flow | $391M | $248M |
| Net income | $331M | −$101M |
| Growth | ||
| Revenue growth | −7.0% | 3.7% |
| 5-year growth | 7.3% | 3.3% |
| Share count change | −2.7% | −4.1% |
| Profitability | ||
| Gross margin | 25.3% | 7.4% |
| Operating margin | 16.7% | 0.1% |
| Net margin | 8.9% | −1.5% |
| FCF margin | 10.5% | 3.7% |
| Return on capital | 15.9% | 0.1% |
| Return on equity | 22.3% | −5.2% |
| Balance sheet | ||
| Net debt | $878M | $2.7B |
| Net debt / EBITDA | 1.1x | 5.1x |
| Dividends and buybacks | $264M | $142M |
| Valuation & quality | ||
| P/E | 12.9x | — |
| Piotroski F-score | 6 | 4 |
FY16
CBT $2.4B
OLN $5.6B
FY17
CBT $2.7B
OLN $6.3B
FY18
CBT $3.2B
OLN $6.9B
FY19
CBT $3.3B
OLN $6.1B
FY20
CBT $2.6B
OLN $5.8B
FY21
CBT $3.4B
OLN $8.9B
FY22
CBT $4.3B
OLN $9.4B
FY23
CBT $3.9B
OLN $6.8B
FY24
CBT $4.0B
OLN $6.5B
FY25
CBT $3.7B
OLN $6.8B
CBT
OLN
FY16
CBT 10.2%
OLN 1.9%
FY17
CBT 12.4%
OLN 4.7%
FY18
CBT 4.4%
OLN 9.8%
FY19
CBT 9.2%
OLN 2.9%
FY20
CBT 0.8%
OLN −13.0%
FY21
CBT 13.3%
OLN 20.8%
FY22
CBT 9.0%
OLN 19.0%
FY23
CBT 13.4%
OLN 10.4%
FY24
CBT 15.4%
OLN 4.5%
FY25
CBT 16.7%
OLN 0.1%
CBT
OLN
FY16
CBT $280M
OLN $325M
FY17
CBT $201M
OLN $355M
FY18
CBT $69.0M
OLN $523M
FY19
CBT $139M
OLN $232M
FY20
CBT $177M
OLN $134M
FY21
CBT $62.0M
OLN $1.5B
FY22
CBT −$111M
OLN $1.7B
FY23
CBT $351M
OLN $738M
FY24
CBT $451M
OLN $308M
FY25
CBT $391M
OLN $248M
CBT
OLN
FY16
CBT 9.4%
OLN 1.5%
FY17
CBT 13.8%
OLN 5.0%
FY18
CBT 3.3%
OLN 8.4%
FY19
CBT 10.7%
OLN 2.5%
FY20
CBT 0.9%
OLN −11.1%
FY21
CBT 16.4%
OLN 30.0%
FY22
CBT 12.4%
OLN 27.7%
FY23
CBT 22.2%
OLN 11.8%
FY24
CBT 19.5%
OLN 4.6%
FY25
CBT 15.9%
OLN 0.1%
CBT
OLN
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.